GQG Partners
HZNP

GQG Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

GQG Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,680
Closed -$513K – 108
2021
Q3 		$513K Buy
4,680
+1,712
+58% +$178K ﹤0.01% 70
2021
Q2 		$278K Buy
+2,968
New +$273K ﹤0.01% 76

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GQG Partners's HZNP Position: Q4 2021 in Review

GQG Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2021, closing a stake of 4,680 shares — an estimated $513K sold.

GQG Partners first reported a position in HZNP in Q2 2021 and held it in 2 quarters. The position peaked at $513K in Q3 2021. 610 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

  • GQG Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • GQG Partners sold 4,680 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $513K.
  • GQG Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 2 quarters.
  • GQG Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $513K in Q3 2021.
  • 610 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on GQG Partners's 13F filing for Q4 2021, filed 14 Feb 2022.